OncRef

Clinical Trial: NCT03161353

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy.

Status:

ACTIVE NOT RECRUITING

Phase:

Phase 2

Lead Sponsor:MedSIR
Information Provided By:MedSIR
Last Update Posted:2025-04-23

Study Overview

Brief Summary

The study assess the early metabolic effects of neoadjuvant treatment with trastuzumab and pertuzumab (± endocrine therapy) on the primary tumor and axillary lymph nodes and their predictive value for pathologic complete response (pCR) in the breast and axilla.

And also assess 3-year invasive disease-free survival (iDFS) in patients with HER2-positive (HER: human epidermal receptor) breast cancer treated with neoadjuvant trastuzumab and pertuzumab (± endocrine therapy) using a FDG-PET response-adapted strategy.

Official Title

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive (Human Epidermal Receptor) Breast Cancer: FDG-PET Response-adapted Strategy. The PHERGain Study

Conditions

Breast Cancer

Intervention / Treatment

  • Drug: Perjeta
  • Drug: Herceptin
  • Drug: Docetaxel
  • Drug: Carboplatin
  • Drug: Letrozole
  • Drug: Tamoxifen

Other Study ID Numbers

  • MedOPP096
  • 2016-002676-27
  • 2016

Start Date (Actual)

2017-06-26

Primary Completion Date (Actual)

2023-11-01

Study Completion Date (Estimated)

2026-11-01

Enrollment (Actual)

377

Study Type

Interventional

Phase

Phase 2